A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions
Rheumatoid ArthritisPsoriatic ArthritisCrohn's DiseaseAxial SpondyloarthritisPlaque Psoriasis
Interventions
DRUG

Pharmacokinetics of certolizumab pegol

"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."

Trial Locations (9)

27710

Up0085 103, Durham

55455

Up0085 104, Minneapolis

73104

Up0085 101, Oklahoma City

Unknown

Up0085 500, Paris

Up0085 202, Freiburg im Breisgau

Up0085 201, Hamburg

Up0085 900, Rotterdam

Up0085 800, Barcelona

Up0085 300, Bern

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04163016 - A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) | Biotech Hunter | Biotech Hunter